Recce Pharmaceuticals (#ASX: $RCE) is pioneering a New Class of Synthetic Anti-Infectives to combat #antibioticresistant #superbugs
Australia
Joined April 2017
- Tweets2.1K
- Following1.1K
- Followers1.7K
- Likes2.4K
Pinned Tweet
We're fighting antibiotic-resistant #superbugs with our innovative synthetic anti-infectives! 💊 🔬✨ #Innovation #AntibioticResistance #UTI #DFI
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review tinyurl.com/28252q7p @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals has submitted data from 75 patients for independent DMC review of its Phase 3 diabetic foot infection trial, following encouraging blinded clinical outcomes and a positive safety profile.
@ReccePharma
#ASX #RCE #Biotech
#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), advises that a review of blinded data of its current Phase III trial undertaken by clinical experts and a statistician indicates strong efficacy along with a very positive safety profile.
Read the full ann: recce.com.au/company-announc…
Recce Pharmaceuticals (ASX: RCE) CEO James Graham will be presenting at the MST Biotech & Healthcare Webinar – The Infection Playbook.
Join James alongside Dr David Foster (Island Pharmaceuticals), Doug Ward (Lumos Diagnostics) and Brent Barnes (Clever Culture Systems) as they discuss innovation across key areas of healthcare and biotechnology.
Tuesday, 20 October 2026
11:00 AM AEDT
Register here: mstfinancial-au.zoom.us/webi…
Bringing new antibacterial technologies to market requires more than scientific innovation.
disAMR explores the pathway from clinical development to commercialisation.
Read more: disamr.com/articles/building…
#AMR #Biotechnology
ONE WEEK TO GO!
Recce Pharmaceuticals (ASX: RCE) is heading to Hong Kong Ignite Summit 2026!
CEO James Graham will present Recce’s latest clinical developments and progress in advancing a new class of synthetic anti-infectives.
Event: 14–15 October 2026
RCE Company Presentation: 14 October | 2:40 PM (HKT)
Venue: Grand Hyatt Hong Kong, Wan Chai
We look forward to connecting with investors and industry professionals!
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals advances R327 as diabetes and antibiotic resistance burdens converge tinyurl.com/2dl5nsvz @ReccePharma #RCE #RECEF #ASX #ASXNews
Recce Pharmaceuticals’ 2026 Annual Report is now available. Discover our progress over the past year, key milestones achieved, and what lies ahead.
recce.com.au/company-announc…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director and CEO James Graham outlines the next milestones as patient recruitment, dosing and Phase 3 trial activities continue.
@ReccePharma
#ASX #RCE #Biotechnology
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director and CEO James Graham discusses HREC approval of the amended Phase 3 DFI trial design and R327G’s clinical development pathway.
@ReccePharma
#ASX #RCE #Biotechnology
Recce Pharmaceuticals Ltd retweeted
The amendment adds a randomised, active-controlled, non-inferiority study in DFI, enrolling a total of 208 participants randomised between R327G and a physician-selected antibiotic.
@ReccePharma #ASX #health
stockhead.com.au/resources/r…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals secures HREC approval for expanded Phase 3 diabetic foot infection trial tinyurl.com/266pwpnm @ReccePharma #RCE #RECEF #ASX #ASXNews
#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce that the Human Research Ethics Committee (HREC) has approved an amendment to the protocol for the Company's pivotal Phase 3 clinical trial of RECCE® 327 Topical Gel (R327G) for the treatment of Diabetic Foot Infections (DFI) in Australia.
Read the full ann here: recce.com.au/company-announc…
People living with diabetes are at greater risk of serious infections
High blood sugar can impair immune function and slow the body's ability to heal wounds, increasing the risk of complications.
This is one reason infection prevention is an important part of diabetes care.
#Diabetes #DFI #DiabeticFoot #Infection #AMR
A diabetic foot infection can be more than a health challenge. It can be a financial one too.
In Indonesia, the average cost of hospital treatment for a diabetic foot infection is approximately USD $4,100.
For many families, the impact extends far beyond the hospital.
#DFI #Diabetes #Indonesia #HealthcareEconomics #AMR
#ASX Announcement - Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) highlights the release of a five-year, US$66.9 billion medical countermeasures funding strategy by the U.S. Administration for Strategic Preparedness and Response (ASPR), the preparedness arm of the U.S. Department of Health and Human Services.
Access our InvestorHub here: lnkd.in/gxH35aDY
What does "mechanism of action" actually mean?
It's the way a drug produces its effect. For antibiotics, that means what it targets in bacteria and how it stops or kills them.
Resistance is often linked to a specific mechanism.
A new mechanism may help overcome existing resistance challenges.
#MechanismOfAction #AMR #Antibiotics #InfectiousDisease
ICYMI - Recce's Q4 FY26 Investor Webinar recording is now live — clinical, commercial and IP updates from our leadership team.
Watch here: youtube.com/watch?v=vZDMAJtv…
#ASX Announcement - Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), is pleased to announce a live online webinar.
The event will be held online via Zoom on 21 July 2026 at 2:30PM AEST and will be recorded for those who cannot attend.
To attend the webinar, please register using the link below: us02web.zoom.us/webinar/regi…
Recce Pharmaceuticals Ltd retweeted
$RCE Recce Pharmaceuticals Managing Director & CEO James Graham on 3.7M ATO refund and impact on cash position and funding pathway.
@ReccePharma
#ASX #RCE #Biotech